Top 5 Biotech Stocks to Add to Your Watchlist

Biotechnology is a booming industry in the world. India is no exception to this.

With over 5,000 biotech companies, including more than 4,000 startups, India is a major hub of biotech innovation.

These companies are involved in various activities, including research and development, production, and commercialisation of biotechnology products and services.

Government initiatives to spur innovation have also helped encourage the growth of the biotechnology industry in India.

To reap the benefits of this sunrise sector, here are the top five biotech stocks in India.

#1 Panacea Biotech

Leading the list is Panacea Biotech.

Panacea Biotech is a leading biotechnology company in India. Founded in 1984, the company has grown to become one of the largest healthcare companies in the world.

The company specialises in developing and manufacturing innovative pharmaceuticals and biologics for human and animal health.

Its product portfolio includes everything from vaccines to generics and diagnostics. They also offer services such as drug discovery, contract research and development, and clinical trials.

The company's current focus lies in addressing unmet medical needs and combating complex diseases through its diverse biotech portfolio.

To improve this product portfolio, the company has consistently invested in state-of-the-art technology and infrastructure.

Also, to increase its product reach in the international market, the company has established various research and development centres in the US, Europe, Latin America, China, and Southeast Asia.

In the last three years, the company's revenue has grown at a compound annual growth rate (CAGR) of 13.1%, led by new order wins for vaccines across all geographies.

Its net profit has grown at a CAGR of 206.3%, driven by operational efficiency and cost optimisation measures.

Return ratios have also remained strong, with return on equity (RoE) and return on capital employed (RoCE) at 127% and 184.6%, respectively.

Panacea Biotech Financial Snapshot (2018-2022)

Particulars	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar
Total revenues (Rs in m)	5,977	4,618	5,744	6,348	6,722
Growth (%)	-	-22.7	24.4	10.5	5.9
Net Profit (Rs in m)	-762	375	-1,946	-1,462	10,779
Net profit margin (%)	-12.9	8.2	-35.8	-23.4	163

Source: Equitymaster

Going forward, to expand its biotech portfolio, the company is working on increasing its capacity in North American, and European markets. It also plans to focus on pharmaceutical products which are already doing well.

For more details, see the Panacea Biotech company fact sheet and quarterly results.

#2 ANG Lifesciences India

Second on the list is ANG Lifesciences India.

ANG Lifesciences India is a prominent biotechnology company known for its comprehensive and diverse portfolio of innovative biotech solutions.

In its biotech portfolio, ANG Lifesciences encompasses a wide range of offerings across various areas of healthcare. One key aspect of their portfolio is the development of advanced therapeutics.

ANG Lifesciences is dedicated to researching and creating novel biopharmaceuticals, including therapeutic proteins, antibodies, and other biotherapeutic molecules.

In the last three years, the company's revenue has grown at a CAGR of 42.8%, driven by increasing demand.

The net profit has grown at a CAGR of 92.5% due to the falling raw material costs and better product mix.

Its RoE and RoCE currently stand at 48.1% and 59.7%, respectively.

The company's current debt-to-equity ratio stands at 0.9x.

ANG Lifesciences India Financial Snapshot (2018-2022)

Particulars	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar
Total revenues (Rs in m)	767	1,219	1,273	1,550	3,552
Growth (%)	-	58.9	4.4	21.8	1.3
Net Profit (Rs in m)	37	56	61	73	403
Net profit margin (%)	4.9	4.6	4.8	4.7	11.4

Source: Equitymaster

Going forward, the company is working on increasing its sales and developing new drugs to expand its portfolio.

For more details, see the ANG Lifesciences India company fact sheet and quarterly results.

#3 Syngene International

Third on the list is Syngene International.

Syngene International is a leading global contract research organization (CRO) based in India with a strong focus on the biotech sector. The company specialises in integrated discovery, development, and manufacturing services for biopharmaceuticals, small molecules, and antibody-drug conjugates (ADCs).

In the biotech field, Syngene offers a wide range of services to support the research and development of novel therapies. This includes early-stage discovery services, high-throughput screening, and hit-to-lead optimisation.

The company specialises in molecular biology, cell biology, and bioinformatics.

Syngene also provides services for process development, formulation development, and manufacturing biologics.

Currently, Syngene has invested in advanced technologies such as genomics, proteomics, and structural biology to strengthen its capabilities in biotech research.

These technologies enable Syngene to offer services in areas such as genomics analysis, protein expression and purification.

In the last five years, the company's revenue has grown at a CAGR of 12.6%, driven by continuous product launches. The net profit has risen at a CAGR of 6.1%, driven by improved margins.

Its RoE and RoCE currently stand at 12.3% and 13.6%, respectively. The company's current debt-to-equity ratio stands at 0.2x.

Syngene International Financial Snapshot (2018-2022)

Particulars	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar
Total revenues (Rs in m)	15,592	19,018	21,080	22,676	27,126
Growth (%)	-	21.9	10.8	7.5	19.6
Net Profit (Rs in m)	3,725	4,154	5,169	4,692	4,844
Net profit margin (%)	21.5	18.2	20.5	18.5	15.2

Source: Equitymaster

Going forward, the company aims to focus on its research and development efforts, to strengthen their product portfolio in the biotech field.

With the growing demand for innovative therapies and the increasing complexity of drug development, it plans to strengthen its offering.

For more details, see the Syngene International company fact sheet and quarterly results.

#4 GSK Pharma

Fourth on the list is GSK Pharma.

GlaxoSmithKline (GSK) Pharmaceuticals is one of the largest pharmaceutical companies globally and operates in prescription medicines, vaccines, and consumer healthcare products.

GSK has a significant presence in the biotech space through its research and development efforts and collaborations.

In the biotech space, GSK focuses on the discovery and development of innovative therapies using biotechnology and genetic engineering techniques.

It has expertise in genomics, proteomics, and bioinformatics, which it utilizes to identify potential drug targets and develop new therapies.

GSK has a robust pipeline of biotech-based drugs and therapies across various therapeutic areas, including oncology, immunology, infectious diseases, respiratory diseases, and rare diseases.

Further, the company collaborates with academic institutions, biotech companies, and other pharmaceutical companies to enhance its biotech capabilities and expand its pipeline.

All these efforts have led to a healthy financial performance. The revenue has grown at a CAGR of 1.6%, driven by new product launches.

The net profit has grown at a CAGR of 59.8% during the same time due to the increasing product margin.

Its RoE and RoCE currently stand at 14.3% and 29.3%, respectively. Despite investing heavily in capex, the company remains debt-free.

GSK Pharma Financial Snapshot (2018-2022)

Particulars	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar
Total revenues (Rs in m)	29,018	32,304	33,034	30,362	33,538
Growth (%)	-	10.4	2.3	-8	10.4
Net Profit (Rs in m)	5,400	6,827	3,058	4,540	7,790
Net profit margin (%)	12.3	14.2	2.9	9.8	11.6

Source: Equitymaster

Going forward, the company plans to bolster its pipeline by increasing its ties. It also plans to launch various products in the international market.

For more details, see the GSK Pharma company fact sheet and quarterly results.

#5 Biocon

Last on the list is Biocon.

Biocon is a leading biopharmaceutical company based in India. Founded in 1978, the company has grown to become one of Asia's largest and most successful companies in the healthcare sector.

Its core focus is to develop novel biologics, small molecule APIs, and biosimilars for global markets. The company has a strong presence across India, with operations in over 25 countries globally.

Its product portfolio includes therapeutics, insulin, generic API, and biopharmaceuticals for infectious diseases, cancer. The company is also actively engaged in contract research and manufacturing services (CRAMS), bio-agriculture, and bio-industrial products.

In the last three years, the company's revenue has grown at a CAGR of 14.1%, driven by high demand in the international market due.

However, the net profit has shown a de-growth of 5.5%, affected by an increase in raw material costs due to inflation.

Its RoE and RoCE stand at 9.4% and 8.6%, respectively. Its current debt-to-equity ratio stands at 0.6x.

Biocon Financial Snapshot (2018-2022)

Particulars	18-Mar	19-Mar	20-Mar	21-Mar	22-Mar
Total revenues (Rs in m)	43,233	59,287	68,080	77,483	88,743
Growth (%)	-	37.1	14.8	13.8	14.5
Net Profit (Rs in m)	4,531	10,026	8,998	8,462	7,716
Net profit margin (%)	11	18.2	14.3	11.8	9.4

Source: Equitymaster

The company has a strategic plan in place going forward to enhance its presence and expand its activities in the biotech space.

The company aims to capitalise on the growing demand for biotech products and services by focusing on several key areas.

Biocon also focuses on expanding its manufacturing capabilities. The company has made substantial investments in developing world-class manufacturing facilities that comply with global quality standards.

For more details, see the Biocon company fact sheet and quarterly results.

Snapshot of Biotech Stocks on Equitymaster's Stock Screener

Here's a quick view of the above companies based on their financials.

Please note that these parameters can be changed according to your selection criteria.

This will help you identify and eliminate stocks not meeting your requirements and emphasise those stocks well inside the metrics.

To conclude

India's biotech sector is expected to double in size by 2025, indicating significant growth potential.

The sector is expected to benefit from the growing demand for new and innovative products from the medical, pharmaceutical, agriculture, and food industries.

Moreover, the government's focus on protecting intellectual property rights is expected to lead to an increase in biotech-related patents.

Initiatives such as Atmanirbhar Bharat, Make in India, Ayushman Bharat, and Startup India will foster momentum.

While the sector shows promising prospects, investors need to conduct their own research before making investment decisions.

And to know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...